Vac­cines – Ther­a­peu­tics – Biosimilars

Suc­cess­ful clin­i­cal tri­als at EMA and US-FDA as well as mar­ket­ing autho­riza­tions for prod­ucts devel­oped for our clients have been achieved for var­i­ous biopharmaceuticals.

Pro­duc­tion cell lines and process­es devel­oped at ARTES result in high­ly immuno­genic vac­cines with cost of goods of sig­nif­i­cant­ly less than 1 Euro per dose.

Biosim­i­lar process­es lead to authen­tic prod­ucts com­ply­ing to inter­na­tion­al phar­ma­copeia and are man­u­fac­tured at extreme­ly afford­able cost of goods (< 50% of the originator).